David Dai
Stock Analyst at UBS
(3.09)
# 2,620
Out of 5,125 analysts
119
Total ratings
47.7%
Success rate
3.7%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Rated: Hold | $15 | $12.04 | +24.58% | 3 | Nov 10, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $27 | $11.23 | +140.43% | 9 | Nov 9, 2026 | |
| BNTX BioNTech SE | Reiterated: Buy | $135 → $125 | $87.21 | +43.33% | 5 | Nov 4, 2026 | |
| IOVA Iovance Biotherapeutics | Rated: Hold | $7 → $8 | $8.08 | -0.99% | 5 | Nov 3, 2026 | |
| SNDX Syndax Pharmaceuticals | Reiterated: Hold | $33 | $9.49 | +247.73% | 6 | Nov 2, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $15 | $7.57 | +98.15% | 9 | Oct 29, 2026 | |
| SMMT Summit Therapeutics | Reiterated: Buy | $33 | $17.83 | +85.08% | 12 | Oct 26, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Buy | $8 | $0.7864 | +917.29% | 5 | Oct 23, 2026 | |
| NBTX Nanobiotix | Reiterated: Hold | $30 | $32.87 | -8.73% | 6 | Sep 25, 2026 | |
| ENGN enGene Therapeutics | Rated: Hold | $2 | $1.67 | +19.76% | 5 | Sep 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $90 | $72.64 | +23.90% | 5 | Aug 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $128 | $136.64 | -6.32% | 3 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $23 → $31 | $15.88 | +95.21% | 6 | Jul 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $30.65 | +46.82% | 2 | Jun 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $31.00 | $14.17 | +118.77% | 13 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $45 | $14.75 | +205.08% | 2 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $34 | $250.83 | -86.45% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $546 | $547.89 | n/a | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $112 | $170.87 | n/a | 1 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $31.75 | n/a | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | ¥2,690 | ¥5,998 | n/a | 6 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ¥34,600 | ¥9,206 | n/a | 1 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | ¥3,900 | ¥4,245 | n/a | 1 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $7.02 | n/a | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $5 | $2.42 | n/a | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $1.35 | n/a | 1 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $54 | $39.39 | n/a | 2 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $28 | $3.00 | n/a | 1 | Mar 30, 2022 |
Janux Therapeutics
Nov 10, 2026
Rated: Hold
Price Target: $15
Current: $12.04
Upside: +24.58%
Cullinan Therapeutics
Nov 9, 2026
Reiterated: Buy
Price Target: $27
Current: $11.23
Upside: +140.43%
BioNTech SE
Nov 4, 2026
Reiterated: Buy
Price Target: $135 → $125
Current: $87.21
Upside: +43.33%
Iovance Biotherapeutics
Nov 3, 2026
Rated: Hold
Price Target: $7 → $8
Current: $8.08
Upside: -0.99%
Syndax Pharmaceuticals
Nov 2, 2026
Reiterated: Hold
Price Target: $33
Current: $9.49
Upside: +247.73%
Kura Oncology
Oct 29, 2026
Reiterated: Buy
Price Target: $15
Current: $7.57
Upside: +98.15%
Summit Therapeutics
Oct 26, 2026
Reiterated: Buy
Price Target: $33
Current: $17.83
Upside: +85.08%
Perspective Therapeutics
Oct 23, 2026
Reiterated: Buy
Price Target: $8
Current: $0.7864
Upside: +917.29%
Nanobiotix
Sep 25, 2026
Reiterated: Hold
Price Target: $30
Current: $32.87
Upside: -8.73%
enGene Therapeutics
Sep 16, 2026
Rated: Hold
Price Target: $2
Current: $1.67
Upside: +19.76%
Aug 21, 2026
Rated: Buy
Price Target: $90
Current: $72.64
Upside: +23.90%
Aug 5, 2026
Reiterated: Buy
Price Target: $128
Current: $136.64
Upside: -6.32%
Jul 22, 2026
Rated: Buy
Price Target: $23 → $31
Current: $15.88
Upside: +95.21%
Jun 16, 2026
Reiterated: Buy
Price Target: $45
Current: $30.65
Upside: +46.82%
Apr 8, 2026
Reiterated: Buy
Price Target: $31.00
Current: $14.17
Upside: +118.77%
Apr 2, 2026
Reiterated: Hold
Price Target: $45
Current: $14.75
Upside: +205.08%
Jan 7, 2026
Downgraded: Hold
Price Target: $40 → $34
Current: $250.83
Upside: -86.45%
Nov 7, 2025
Reiterated: Buy
Price Target: $546
Current: $547.89
Upside: n/a
Oct 31, 2025
Reiterated: Hold
Price Target: $112
Current: $170.87
Upside: n/a
Oct 24, 2025
Reiterated: Buy
Price Target: $50
Current: $31.75
Upside: n/a
Apr 2, 2025
Reiterated: Hold
Price Target: ¥2,690
Current: ¥5,998
Upside: n/a
Feb 26, 2025
Reiterated: Buy
Price Target: ¥34,600
Current: ¥9,206
Upside: n/a
Jan 15, 2025
Initiated Coverage: Buy
Price Target: ¥3,900
Current: ¥4,245
Upside: n/a
Sep 29, 2022
Initiated Coverage: Buy
Price Target: $5
Current: $7.02
Upside: n/a
Jul 18, 2022
Downgraded: Hold
Price Target: $40 → $5
Current: $2.42
Upside: n/a
May 16, 2022
Reiterated: Buy
Price Target: $40
Current: $1.35
Upside: n/a
May 9, 2022
Reiterated: Buy
Price Target: $54
Current: $39.39
Upside: n/a
Mar 30, 2022
Initiated Coverage: Buy
Price Target: $28
Current: $3.00
Upside: n/a